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To the Editor,
We thank Dr Fukumoto and colleagues for their letter related to 
our manuscript.1,2 There are limited data on sensitivity of alpha-foe-
toprotein (AFP) for hepatocellular carcinoma (HCC) detection in 
patients with cirrhosis who achieved sustained virologic response 
(SVR) after direct-acting antiviral (DAA) therapy for hepatitis C 
virus (HCV) infection.3 Our study was not able to directly address 
whether including AFP in HCC surveillance in this population is asso-
ciated with improved outcomes, for two reasons. First, in our cohort, 
AFP was infrequently used for HCC surveillance (at least in conjunc-
tion with imaging, as we did not consider AFP-only surveillance) with 
median proportion of time covered by both AFP and ultrasound of 
0%. Second, only a small proportion of patients had received DAA 
therapy as the study period was largely in the pre-DAA era.
With the caveat that data are limited in patients with HCV and 
SVR, we believe that the balance of evidence favours inclusion of 
AFP in HCC surveillance. In a recent meta-analysis, AFP plus ul-
trasound demonstrated higher sensitivity than ultrasound alone 
for early-stage HCC detection (63% vs 45%).4 Longitudinal AFP 
measurement may further increase sensitivity for HCC detection.5 
Further studies are required to establish sensitivity and specificity of 
ultrasound with or without AFP in patients with HCV cirrhosis after 
SVR with DAA therapy, to determine the benefits of incorporating 
AFP into HCC surveillance in this population.
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